Maropitant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Maropitant
Maropitant.png
Systematic (IUPAC) name
(7R,8S)-N-[(5-tert-Butyl-2-methoxyphenyl)methyl]-7-[di(phenyl)methyl]-1-azabicyclo[2.2.2]octan-8-amine
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
  • veterinary prescription only
Routes Oral, subcutaneous
Identifiers
ATCvet code QA04AD90
PubChem CID 23724948
ChemSpider 176804 YesY
UNII 4XE2T9H4DH YesY
Chemical data
Formula C32H40N2O 
Mol. mass 468.67 g/mol
 YesY (what is this?)  (verify)

Maropitant (trade name Cerenia in the US and other countries), used as maropitant citrate (USAN), is a neurokinin (NK1) receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs,[1][2] and more recently has also been approved for use in cats.[3]

Maropitant also has anti-nociceptive (analgesic) properties. In a 2012 study, parenteral maropitant decreased the minimum alveolar concentration (MAC) of sevoflurane in a pain-response model.[citation needed] Epidural administration had no effect. It has also been shown to decrease the MAC of sevoflurane in a cat spay and dog spay model. Whether it has analgesic properties in awake animals remains to be proven, but anecdotal evidence indicates that it is being used for analgesia by many veterinarians. Its mode of action is through inhibition of substance P binding at the NK1 receptor.

See also[edit]

References[edit]

External links[edit]